Advertisement

Archives of Dermatological Research

, Volume 310, Issue 6, pp 485–493 | Cite as

CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study

  • Anna Niederkorn
  • Julia Frühauf
  • Gerold Schwantzer
  • Nora Wutte
  • Clemens Painsi
  • Stefan Werner
  • Martin Stradner
  • Andrea Berghold
  • Josef Hermann
  • Elisabeth Aberer
Original Paper
  • 97 Downloads

Abstract

Serum levels of the IFN-regulated cytokine CXCL13 have been found to correlate with SLEDAI and renal involvement in systemic lupus erythematosus. This study investigates whether CXCL13 can also be a marker of disease activity in patients with subacute cutaneous or chronic cutaneous lupus erythematosus (SCLE, CCLE). We analysed CXCL13 levels in 60 patients’ sera (18 SLE, 19 SCLE, 23 CCLE) at five time points within 1 year and correlated these levels with disease activity scores and laboratory markers. Clinical scores with no/mild, moderate or high/severe disease activity were categorized by SLEDAI in SLE, by CLASI in SCLE/CCLE. CXCL13 levels were significantly higher in SLE (median 122.5, IQR 88.0–239.0 pg/ml) than in CCLE patients (median 69.0, IQR 60.0–102.0 pg/ml) (p = 0.006). CXCL13 levels were elevated in 59% (41/70) of SLE patient visits with mild or no disease activity, but in 90% (9/10) with high disease activity. CXCL13 levels correlated with ECLAM, dsDNA-antibodies, and inversely with complement factors C3 and C4 in SLE, and with IgA and ESR in SCLE. In CCLE CXCL13 did not correlate with CLASI or laboratory markers. One SCLE and two CCLE patients with CXCL13 levels > 500 pg/ml had conversion to SLE or an underlying autoimmune disease. CXCL13 seems to be a useful marker of disease activity in SLE, but not in SCLE and CCLE. Conversion from normal to elevated CXCL13 may indicate a flare of SLE. Whether high CXCL13 levels in cutaneous LE indicate the development of SLE should be further investigated.

Keywords

CXCL13 Systemic lupus erythematosus Cutaneous lupus erythematosus Activity biomarker SLEDAI CLASI 

Notes

Acknowledgements

We greatly acknowledge the laboratory work of Ingrid Krainberger and Monika Joch.

Funding

No funding was provided for this project.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Ethical approval was given by the ethics commettee of the Medical University of Graz (Approval No. 19-338 ex 07/08).

Informed consent

All patients gave written consent to participate in the study.

References

  1. 1.
    Ahearn JM, Liu CC, Kao AH, Manzi S (2012) Biomarkers for systemic lupus erythematosus. Transl Res 159:326–342CrossRefPubMedGoogle Scholar
  2. 2.
    Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G, McGinnis K, Richardson S, Treat J, Vittorio C, Van Voorhees A, Werth VP (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889–894CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Albrecht J, Werth VP (2007) Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther 20:93–101CrossRefPubMedGoogle Scholar
  4. 4.
    Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258–265CrossRefGoogle Scholar
  5. 5.
    Aust G, Sittig D, Becherer L, Anderegg U, Schutz A, Lamesch P, Schmucking E (2004) The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases. Eur J Endocrinol 150:225–234CrossRefPubMedGoogle Scholar
  6. 6.
    Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60:3098–3107CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640CrossRefPubMedGoogle Scholar
  8. 8.
    Chong BF (2014) Understanding how cutaneous lupus erythematosus progresses to systemic lupus erythematosus. JAMA Dermatol 150:296CrossRefPubMedGoogle Scholar
  9. 9.
    Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D (1996) Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 39:370–378CrossRefPubMedGoogle Scholar
  10. 10.
    Ezzat M, El-Gammasy T, Shaheen K, Shokr E (2011) Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement. Lupus 20:845–854CrossRefPubMedGoogle Scholar
  11. 11.
    Fang C, Luo T, Lin L (2017) The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus: a STROBE-compliant article. Medicine (Baltimore) 96:e8675CrossRefGoogle Scholar
  12. 12.
    Freutel S, Gaffal E, Zahn S, Bieber T, Tuting T, Wenzel J (2011) Enhanced CCR5+/CCR3 + T helper cell ratio in patients with active cutaneous lupus erythematosus. Lupus 20:1300–1304CrossRefPubMedGoogle Scholar
  13. 13.
    Gladman DD, Hirani N, Ibanez D, Urowitz MB (2003) Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 30:1960–1962PubMedGoogle Scholar
  14. 14.
    Gladman DD, Urowitz MB, Kagal A, Hallett D (2000) Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 27:377–379PubMedGoogle Scholar
  15. 15.
    Greisen SR, Schelde KK, Rasmussen TK, Kragstrup TW, Stengaard-Pedersen K, Hetland ML, Horslev-Petersen K, Junker P, Ostergaard M, Deleuran B, Hvid M (2014) CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ‘window of opportunity’. Arthritis Res Ther 16:434CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Harris VK, Sadiq SA (2014) Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther 18:605–617CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ho A, Barr SG, Magder LS, Petri M (2001) A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 44:2350–2357CrossRefPubMedGoogle Scholar
  18. 18.
    Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, Troxel AB, Werth VP (2011) Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 147:203–208CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kramer JM, Klimatcheva E, Rothstein TL (2013) CXCL13 is elevated in Sjogren’s syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol 94:1079–1089CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kuhn A, Ruzicka T Classification of cutaneous lupus erythematosus. In: Kuhn A, Lehman P, Ruzicka T eds, (ed). Cutaneous lupus erythematosus: Springer, New York 2004:p 53Google Scholar
  21. 21.
    Kuhn A, Sticherling M, Bonsmann G (2007) Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges 5:1124–1137CrossRefPubMedGoogle Scholar
  22. 22.
    Lam GK, Petri M (2005) Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 23:S120–132Google Scholar
  23. 23.
    Lee HT, Shiao YM, Wu TH, Chen WS, Hsu YH, Tsai SF, Tsai CY (2010) Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 37:45–52CrossRefPubMedGoogle Scholar
  24. 24.
    Li JQ, Hu SY, Wang ZY, Lin J, Jian S, Dong YC, Wu XF, Lan D, Cao LJ (2015) MicroRNA-125-5p targeted CXCL13: a potential biomarker associated with immune thrombocytopenia. Am J Transl Res 7:772–780PubMedPubMedCentralGoogle Scholar
  25. 25.
    Liu CC, Manzi S, Ahearn JM (2005) Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 17:543–549CrossRefPubMedGoogle Scholar
  26. 26.
    Mullegger RR, Means TK, Shin JJ, Lee M, Jones KL, Glickstein LJ, Luster AD, Steere AC (2007) Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma. Infect Immun 75:4621–4628CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Rao V, Gordon C (2014) Advances in the assessment of lupus disease activity and damage. Curr Opin Rheumatol 26:510–519CrossRefPubMedGoogle Scholar
  28. 28.
    Robinson ES, Werth VP (2015) The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine 73:326–334CrossRefPubMedGoogle Scholar
  29. 29.
    Roy A (2006) Estimating correlation coefficient between two variables with repeated observations using mixed effects model. Biom J 48:286–301CrossRefPubMedGoogle Scholar
  30. 30.
    Sansonno D, Tucci FA, Troiani L, Sansonno L, Dammacco F (2008) Current and emerging therapeutic approaches in HCV-related mixed cryoglobulinemia. Curr Med Chem 15:117–126CrossRefPubMedGoogle Scholar
  31. 31.
    Schiffer L, Kielstein JT, Haubitz M, Luhrs H, Witte T, Haller H, Kumpers P, Schiffer M (2011) Elevation of serum CXCL13 in SLE as well as in sepsis. Lupus 20:507–511CrossRefPubMedGoogle Scholar
  32. 32.
    Schiffer L, Kumpers P, Davalos-Misslitz AM, Haubitz M, Haller H, Anders HJ, Witte T, Schiffer M (2009) B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transpl 24:3708–3712CrossRefGoogle Scholar
  33. 33.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMedGoogle Scholar
  34. 34.
    Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Neri R, Bombardieri S (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10:541–547PubMedGoogle Scholar
  35. 35.
    Wieczorek IT, Propert KJ, Okawa J, Werth VP (2014) Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol 150:291–296CrossRefPubMedGoogle Scholar
  36. 36.
    Wu X, Guo J, Ding R, Lv B, Bi L (2015) CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice. Acta Histochem 117:732–737CrossRefPubMedGoogle Scholar
  37. 37.
    Wutte N, Berghold A, Loffler S, Zenz W, Daghofer E, Krainberger I, Kleinert G, Aberer E (2011) CXCL13 chemokine in pediatric and adult neuroborreliosis. Acta Neurol Scand 124:321–328CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Anna Niederkorn
    • 1
  • Julia Frühauf
    • 2
  • Gerold Schwantzer
    • 3
  • Nora Wutte
    • 1
  • Clemens Painsi
    • 4
  • Stefan Werner
    • 5
  • Martin Stradner
    • 6
  • Andrea Berghold
    • 3
  • Josef Hermann
    • 6
  • Elisabeth Aberer
    • 1
  1. 1.Department of DermatologyMedical University of GrazGrazAustria
  2. 2.Currently Private Medical Office of DermatologyMaria EnzersdorfAustria
  3. 3.Institute for Medical Informatics, Statistics and DocumentationMedical University of GrazGrazAustria
  4. 4.Currently Department of DermatologyHospital Klagenfurt am WörtherseeKlagenfurtAustria
  5. 5.Currently Private Medical Office of DermatologyGrazAustria
  6. 6.Department of Rheumatology and ImmunologyMedical University of GrazGrazAustria

Personalised recommendations